Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies

Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies

Show other versions (1)

Saved in:

Bibliographic Details
Main Authors:	Martin K. H. Ho, Araniy Santhireswaran, Tara Gomes, Muhammad Mamdani, Mina Tadrous
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310029/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies.
by: Martin K H Ho, et al.
Published: (2025-01-01)

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
by: Carolyn Tieu, et al.
Published: (2018-01-01)

Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I
by: Ali Rabbani, et al.
Published: (2025-08-01)

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study
by: Han Shan, et al.
Published: (2024-12-01)

Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products
by: V. D. Gusarova, et al.
Published: (2019-03-01)

Safety of Switching from a Reference Biologic to Its Biosimilar: A Systematic Review and Meta-Analysis
by: Sarah Saad Aljahili, et al.
Published: (2025-02-01)

Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: A scoping review.
by: Shenthuraan Tharmarajah, et al.
Published: (2025-01-01)

Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: A scoping review
by: Shenthuraan Tharmarajah, et al.
Published: (2025-01-01)

Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar
by: Herve Bischoff, et al.
Published: (2025-04-01)

Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.
by: Amol A Verma, et al.
Published: (2018-06-01)

An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
by: D. P. Kamilova, et al.
Published: (2021-03-01)

Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
by: Li Liu, et al.
Published: (2025-04-01)

Russian association of endocrinologist draft recommendation on insulin biosimilars using
by: I. I. Dedov, et al.
Published: (2021-02-01)

Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers
by: Arvind Vaidyanathan, et al.
Published: (2024-10-01)

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
by: Neungseon Seo, et al.
Published: (2024-11-01)

Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!
by: Concepcion Castillo-Gallego, et al.
Published: (2020-01-01)

Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
by: Wiktoria Górecka, et al.
Published: (2025-06-01)

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis
by: Nitin Kapoor, et al.
Published: (2025-06-01)

Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab
by: Seungchan Choi, et al.
Published: (2025-08-01)

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
by: A. N. Afanasyeva, et al.
Published: (2022-10-01)

Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016-07-01)

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis
by: Xuan Ye, et al.
Published: (2025-08-01)

A Long-Term Retrospective Real-World Evidence to Understand the Pattern of Insulin Prescription in Patients with Type 2 Diabetes Mellitus: Evaluating the Role of Insulin Initiation
by: Shishir Kumar
Published: (2024-10-01)

Safety profiles of biosimilars vs. their EU reference products: INNs (adalimumab, bevacizumab, trastuzumab, rituximab, infliximab, etanercept)
by: Valentin Kopanarov, et al.
Published: (2025-07-01)

The “Brave New World” of biosimilars: Look before you leap!
by: Lathika Vasu Kamaladevi
Published: (2024-12-01)

Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
by: Giampiero Girolomoni, et al.
Published: (2024-12-01)

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
by: Marina G. Birck, et al.
Published: (2025-07-01)

The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01)

Metformin versus insulin in gestational diabetes mellitus: a systematic review
by: Giovanna Noronha Berti, et al.
Published: (2025-01-01)

Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01)

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients
by: Tamather Almandeel, et al.
Published: (2025-06-01)

The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis
by: Magdalena Kaniewska, et al.
Published: (2017-09-01)

Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries
by: David Beran, et al.
Published: (2025-01-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01)

Application of observational research methods to real-world studies for rare disease drugs: A scoping review protocol.
by: Yuti P Patel, et al.
Published: (2025-01-01)

Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty
by: Lauren N. McGrath, et al.
Published: (2025-07-01)

Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey
by: Hüseyin Kaplan, et al.
Published: (2025-08-01)

Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain
by: Alexis Oliva, et al.
Published: (2024-11-01)

A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
by: Hans C. Ebbers, et al.
Published: (2025-04-01)

Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study
by: Chenxi Li, et al.
Published: (2025-01-01)